Eupraxia Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eupraxia Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11240
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eupraxia Pharmaceuticals Inc (Eupraxia Pharma) is a drug development company that offers pain management solutions. The company’s technology encapsulates pharmaceutical micro particles in a polymer shell which helps to extend drug release from days to months. Its pipeline products include EP-104IAR and EP-104EPI. Eupraxia Pharma’s EP-104IAR is a sustained released non-opioid treatment for pain related to osteoarthritis. The company’s EP-104EPI is a non-opioid sustained release compounds for chronic pain indications. It provides a portfolio of drug candidates in the areas of osteoarthritis, chronic pain, anesthetic and antibiotic, veterinary health, post-surgical pain and anti-infectives. Eupraxia Pharma is headquartered in Victoria, British Columbia, Canada.

Eupraxia Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Eupraxia Pharma Raises Funds in Financing 10
Eupraxia Pharma Raises USD0.02 Million in Venture Financing 11
Eupraxia Pharma Raises Funds through Venture Financing 12
Eupraxia Pharma Raises USD0.4 Million in Venture Financing 13
Eupraxia Pharma Raises Funds through Venture Financing 14
Eupraxia Pharma Raises USD0.01 Million in Venture Financing 15
Licensing Agreements 16
Eupraxia Pharmaceuticals Enters into License Agreement with Auritec Pharmaceuticals 16
Eupraxia Pharmaceuticals Inc – Key Competitors 17
Eupraxia Pharmaceuticals Inc – Key Employees 18
Eupraxia Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eupraxia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Eupraxia Pharma Raises Funds in Financing 10
Eupraxia Pharma Raises USD0.02 Million in Venture Financing 11
Eupraxia Pharma Raises Funds through Venture Financing 12
Eupraxia Pharma Raises USD0.4 Million in Venture Financing 13
Eupraxia Pharma Raises Funds through Venture Financing 14
Eupraxia Pharma Raises USD0.01 Million in Venture Financing 15
Eupraxia Pharmaceuticals Enters into License Agreement with Auritec Pharmaceuticals 16
Eupraxia Pharmaceuticals Inc, Key Competitors 17
Eupraxia Pharmaceuticals Inc, Key Employees 18

List of Figures
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Eupraxia Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Koch Membrane Systems Inc:企業の戦略的SWOT分析
    Koch Membrane Systems Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Publix Super Markets Inc:企業の戦略的SWOT分析
    Publix Super Markets Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • China Digital Culture (Group) Ltd (8175):企業の財務・戦略的SWOT分析
    China Digital Culture (Group) Ltd (8175) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • API Technologies Corp.:戦略・SWOT・企業財務分析
    API Technologies Corp. - Strategy, SWOT and Corporate Finance Report Summary API Technologies Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Phoenix Global Resources Plc (PGR):企業の財務・戦略的SWOT分析
    Phoenix Global Resources Plc (PGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Indivumed GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Indivumed GmbH (Indivumed) is an oncology company that provides solutions for diagnosis and treatment of cancer. The company is involved in the generation, characterization, and analysis of biologic samples from human cancer patients. It offers biospecimen products and clinical data sets; an …
  • Oxurion NV (OXUR):企業の財務・戦略的SWOT分析
    Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Internet Initiative Japan Inc (3774):企業の財務・戦略的SWOT分析
    Internet Initiative Japan Inc (3774) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sysmex Inostics GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Sysmex Inostics GmbH (Sysmex Inostics), formerly Inostics GmbH, a subsidiary of Sysmex Corp, is a molecular diagnostics company that offers blood-based cell-free tumor treatment solutions. The company offers services such as clinical trials, research and development, and testing for physicia …
  • Dnata:企業のM&A・事業提携・投資動向
    Dnata - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dnata Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisin …
  • Daito Trust Construction Co., Ltd.:企業の戦略・SWOT・財務分析
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Zhejiang Yatai Pharmaceutical Co Ltd (002370):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Yatai Pharmaceutical Co Ltd (Yatai Pharmaceutical), formerly Asia-Pacific Pharmaceutical Factory, is a pharmaceutical company. The company develops, researches, and manufactures pharmaceuticals including penicillin, cephalosporins and hormones. It offers transdermal controlled-relea …
  • Apexigen Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of cancer. The company’s lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell responses. It also …
  • First Bank Of Nigeria Ltd
    First Bank Of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report Summary First Bank Of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Tuesday Morning Corporation:企業の戦略・SWOT・財務情報
    Tuesday Morning Corporation - Strategy, SWOT and Corporate Finance Report Summary Tuesday Morning Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Volex plc (VLX):企業の財務・戦略的SWOT分析
    Volex plc (VLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Gemphire Therapeutics Inc (GEMP):企業の財務・戦略的SWOT分析
    Gemphire Therapeutics Inc (GEMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Celcuity Inc (CELC):企業の製品パイプライン分析
    Summary Celcuity Inc (Celcuity) is a cellular analysis company that develops companion diagnostic tests to identify new patient populations for targeted therapies. The company’s CELx signaling function diagnostic platform utilizes a patient’s living tumor cells to identify the specific abnormal cell …
  • Horama SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Horama SA (Horama) is a biotechnology company, which develops gene therapy products based on recombinant adeno-associated virus (rAAV) vectors for the treatment of rare ophthalmic diseases, including retinopathies and maculopathies. Its pipeline gene replacement products include HORA-RPE65, …
  • Medipines Corp-医療機器分野:企業M&A・提携分析
    Summary MediPines Corp (Medipines) develops and commercializes advanced respiratory measurement and monitoring devices. It focuses on the development of portable and non-invasive devices based on pulse oximetry technology. The company’s lead product candidate, Oxistimulator, is a respiratory depress …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆